Search research articles
Contact Us
Filters
Showing results (131-140 of 168) with videos related to
Page
of 17
Sort By:
Plos One
|
May 5, 2012
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device
Brian J Kirby, Mona Jodari, Matthew S Loftus, et al.
British Journal of Cancer
|
January 20, 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
Kyrillus S Shohdy, Dario M Villamar, Yen Cao, et al.
Genes, Chromosomes & Cancer
|
November 10, 2019
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer
Santosh Gupta, Daniel H Hovelson, Gabor Kemeny, et al.
The Journal of Clinical Investigation
|
February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Himisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
Plos One
|
December 10, 2019
Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series
Johannes C van der Mijn, Bashir Al Hussein Al Awamlh, Aleem Islam Khan, et al.
Nature Communications
|
November 26, 2014
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti, Alexandre Matov, Himisha Beltran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2018
Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T Tagawa, Emmanuel S Antonarakis, Ada Gjyrezi, et al.
Cancer
|
November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
Petros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Nature Communications
|
June 8, 2021
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer
Nicholas J Brady, Alyssa M Bagadion, Richa Singh, et al.
Molecular Oncology
|
March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
Johannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 168) with videos related to
Sort By:
Page
of 17
Plos One
|
May 5, 2012
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device
Brian J Kirby, Mona Jodari, Matthew S Loftus, et al.
British Journal of Cancer
|
January 20, 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
Kyrillus S Shohdy, Dario M Villamar, Yen Cao, et al.
Genes, Chromosomes & Cancer
|
November 10, 2019
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer
Santosh Gupta, Daniel H Hovelson, Gabor Kemeny, et al.
The Journal of Clinical Investigation
|
February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Himisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
Plos One
|
December 10, 2019
Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series
Johannes C van der Mijn, Bashir Al Hussein Al Awamlh, Aleem Islam Khan, et al.
Nature Communications
|
November 26, 2014
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti, Alexandre Matov, Himisha Beltran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2018
Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T Tagawa, Emmanuel S Antonarakis, Ada Gjyrezi, et al.
Cancer
|
November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
Petros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Nature Communications
|
June 8, 2021
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer
Nicholas J Brady, Alyssa M Bagadion, Richa Singh, et al.
Molecular Oncology
|
March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
Johannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
Page
of 17